Global Oncology Market Outlook 2025–2030 | Competitive Intelligence, Pipeline & Market Forecast
The global oncology market is projected to grow from USD 228 billion in 2025 to USD 370 billion by 2030 (10.2% CAGR), driven by immuno-oncology, antibody-drug conjugates (ADCs), precision medicine, cell therapies, and biomarker-led treatment strategies. This strategic insight analyzes the top oncology companies, leading brands, therapeutic areas, pipeline landscape, patent expiry outlook, and commercial opportunities shaping the next five years.
Global Oncology Market Outlook 2025–2030
Executive Summary
The oncology industry continues to be one of the fastest-growing pharmaceutical segments globally. Driven by scientific innovation, increasing cancer incidence, precision medicine, and accelerated regulatory approvals, the global oncology market is expected to expand from **USD 228 Billion in 2025** to nearly **USD 370 Billion by 2030**, representing a CAGR of **10.2%**.
Immunotherapy, antibody-drug conjugates (ADCs), targeted therapies, radioligands, and cell therapies continue to reshape treatment paradigms while biosimilars and patent expiries will significantly influence commercial strategies.
---
Market Highlights
---
Top Oncology Companies (2025)
| Rank | Company | Oncology Revenue |
|-------|----------|-----------------|
| 1 | Merck | USD 48.5B |
| 2 | Roche | USD 31.7B |
| 3 | AstraZeneca | USD 24.6B |
| 4 | Bristol Myers Squibb | USD 22.6B |
| 5 | Johnson & Johnson | USD 20.1B |
| 6 | Pfizer | USD 15.7B |
| 7 | Novartis | USD 14.8B |
| 8 | AbbVie | USD 12.5B |
| 9 | Gilead Sciences | USD 11.3B |
| 10 | Eli Lilly | USD 7.9B |
Together these companies account for over **50% of the global oncology market.**
---
Leading Oncology Brands
These brands continue to dominate global oncology revenues through expanding indications and combination therapy strategies.
---
Therapy Area Trends
Current market composition:
Precision medicine and biomarker-guided therapies continue gaining market share.
---
Pipeline Landscape
Current global oncology pipeline:
Pipeline distribution:
---
Strategic Industry Trends
---
Patent Expiry Landscape
Major oncology blockbuster patent expiries are expected between 2026–2031 including:
These losses of exclusivity will create significant opportunities for biosimilars, follow-on biologics, and competitive market entry.
---
Commercial Opportunities
Pharmaceutical companies should prioritize:
---
Strategic Takeaways
The next phase of oncology growth will be driven by innovation rather than volume. Companies investing in precision medicine, ADCs, cell therapy, biomarkers, and AI-enabled commercial intelligence are expected to outperform peers.
Organizations should proactively prepare for upcoming patent cliffs while accelerating differentiated pipeline assets and strategic partnerships.
---
About Medifirm Intelledge Global
Prepared by:
**Medifirm Intelledge Global Private Limited**
Specialists in:
Website:
https://medifirmintelledgeglobal.com